Document › Details
Sygnis AG. (5/4/15). "Press Release: Sygnis Signs Non-exclusive Distribution Agreement with Cambridge Bioscience Ltd. for UK and Ireland". Madrid & Heidelberg.
> Significant expansion of product roll-out into one of the most important life science markets in Europe
> Cambridge Bioscience is a specialized distributor with a strong focus on all areas of life science research
> TruePrime™ as well as SunScript™ products are powerful tools addressing key challenges in next generation sequencing (NGS) and single cell analysis (SCA)
SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced a distribution agreement with Cambridge Bioscience for the commercialization of SYGNIS’ proprietary product portfolio in the UK and Ireland. Since the Department for Business, Innovation & Skills, the UK life science industry is one of the world leaders with more than 4,000 companies, employing around 160,000 people and with a total annual turnover of over £50 billion.
Under the terms of the agreement, Cambridge Bioscience will promote, market, sell and support TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to researchers in molecular biology in the UK and Ireland.
TruePrime™ is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.
SYGNIS’ SunScript™ product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
Cambridge Bioscience is a leading UK based distributor of cutting-edge life science research products including a broad portfolio of innovative products and technologies for molecular biology applications such as NGS, epigenetics, gene regulation, cloning, DNA extraction and purification, amplification, quantification, delivery as well as high-end instrumentation.
“We are very pleased to announce the distribution agreement for an strategically important European key market such as the UK which in addition also represents one of the biggest life science industries worldwide,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Cambridge Bioscience complements our fast growing list of leading international distribution partners and proves the ongoing interest and demand in our proprietary product and technology family.”
TruePrimeTM is the brand name of a revolutionary novel multiple displacement amplification (MDA) technology and one of the key products in SYGNIS’ portfolio. TruePrimeTM is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand-displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include the complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrimeTM shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.
About SunScript™ RT
SunScript™ Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript™ Reverse Transcriptase will be available in two versions. In its RNaseH+ version, the enzyme shows RNA-dependent polymerase activity as well as RNaseH (ribonuclease that cleaves the RNA in a DNA/RNA duplex) activity. This product is optimized for synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions.
SunScript™ RT RNaseH- has been determined to be free of RNaseH activity which permit high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications. In addition, the elimination of RNaseH activity provides SunScriptTM RT RNaseH- with a lower error rate and an improved processivity at higher temperatures that allows resolution of RNA folds and less nonspecific binding by the DNA primer.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30
Record changed: 2016-06-07
More documents for Genetrix (ES) (Group)
-  Sygnis AG. (3/1/17). "Press Release: Sygnis AG Announces Management Changes. David Roth Appointed Chief Financial Officer (CFO) ". Madrid & Heidelberg....
-  Sygnis AG. (2/2/17). "Press Release: Sygnis AG Announces the Launch of TrueHelix". Madrid & Heidelberg....
-  Sygnis AG. (12/21/16). "Press Release: Sygnis AG Acquires Profitable US Life Sciences Tools Company C.B.S. Scientific for US $0.9 Million in Cash and Shares". Madrid & Heidelberg....
-  Sygnis AG. (11/28/16). "Press Release: Sygnis AG Reinforces Its Proteomics Portfolio with Two Patents Granted in Europe and China". Madrid & Heidelberg....
-  Sygnis AG. (11/18/16). "Press Release: Sygnis AG to Present at Upcoming Investor Conferences". Madrid & Heidelberg....
-  Sygnis AG. (11/16/16). "Press Release: Sygnis AG Launches TruePrime Liquid Biopsy Kit targeting Oncology Research and Diagnostics". Madrid & Heidelberg....
-  Sygnis AG. (11/9/16). "Press Release: Sygnis AG Reports Nine Month Results for the Period Ended September 30, 2016". Madrid & Heidelberg....
-  Sygnis AG. (10/27/16). "Press Release: Sygnis AG to Receive €1.9 Million Non-dilutive R&D Funding from the Spanish Government". Madrid & Heidelberg....
-  Sygnis AG. (9/22/16). "Press Release: Sygnis AG Enters into Collaboration Agreement with ECACC for Licensing and Distribution of Caco-2 Cell Line". Madrid & Heidelberg....
-  Sygnis AG. (8/8/16). "Press Release: Sygnis AG Strengthens Management Team with Appointment of Dr. Heikki Lanckriet". Madrid & Heidelberg....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)